RECURRENT ENDOMETRIAL CARCINOMA

This early-stage study is testing a new combination treatment for gynecologic cancers that have returned after previous therapy. Researchers are combining an oral drug called talazoparib with standard radiation therapy to see if it works better together. The main goal is to find …

This early-stage study is testing the safety of combining two cancer drugs (lenvatinib and pembrolizumab) with a short, intense course of pelvic radiation. The goal is to see if this three-part approach is safe and tolerable for people with a specific type of recurrent or inopera…

This large, late-stage trial is comparing three different drug combinations for treating advanced or recurrent endometrial (uterine) cancer that has specific genetic features. It aims to see if adding a drug called bevacizumab to standard chemotherapy and immunotherapy helps pati…

This study is testing whether combining two drugs, nab-sirolimus (given by IV) and letrozole (a daily pill), can help control advanced or recurrent endometrial cancer. It is for patients whose cancer has returned or spread and who have had zero to one prior rounds of chemotherapy…

This trial is a large screening program that matches patients with advanced solid tumors to one of many smaller treatment studies. It uses genetic testing on a patient's tumor to find specific mutations. Patients are then assigned to a drug combination designed to target those mu…

This study is for people whose endometrial (uterine) cancer has returned after treatment. It compares two different immunotherapy approaches to see which is better at controlling the cancer. One group gets a single immunotherapy drug (nivolumab), while the other gets a combinatio…

This study is for women whose ovarian or endometrial cancer has returned or persisted despite prior treatment and has a specific genetic change (a RAS pathway mutation). It aims to see if taking two targeted drugs (selumetinib and olaparib) together works better than taking just …

This early-stage study is testing a new combination of two oral drugs, M1774 and ZEN-3694, for women with recurrent ovarian or endometrial cancer. The main goals are to find the safest and most effective dose and to see how well the drugs work together to stop cancer cell growth.…

This early-stage study is testing a new combination of two drugs, pelcitoclax and cobimetinib, for women with ovarian or endometrial cancer that has returned after prior treatment. The main goals are to find the safest and most effective dose and to check for side effects. Resear…

This study is testing whether combining two drugs, avelumab and M1774, can help control a specific type of recurrent endometrial (uterine) cancer that has a mutation in the ARID1A gene. It is for patients whose cancer has come back after prior treatment, including immunotherapy. …

This study aims to collect tumor tissue samples from patients with various cancers to test a new diagnostic platform called Elephas. The goal is to see how accurately this tool can predict whether patients will respond to immunotherapy treatments before they begin. Researchers wi…